Literature DB >> 25361604

MALT1 protease: equilibrating immunity versus tolerance.

Arianna Bertossi1, Daniel Krappmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25361604      PMCID： PMC4282552          DOI： 10.15252/embj.201490217

Source DB:  PubMed          Journal:  EMBO J        ISSN： 0261-4189            Impact factor:   11.598


× No keyword cloud information.
  14 in total

1.  Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.

Authors:  Maike Jaworski; Ben J Marsland; Jasmine Gehrig; Werner Held; Stéphanie Favre; Sanjiv A Luther; Mai Perroud; Déla Golshayan; Olivier Gaide; Margot Thome
Journal:  EMBO J       Date:  2014-10-15       Impact factor: 11.598

2.  The proteolytic activity of the paracaspase MALT1 is key in T cell activation.

Authors:  Fabien Rebeaud; Stephan Hailfinger; Anita Posevitz-Fejfar; Myriam Tapernoux; Roger Moser; Daniel Rueda; Olivier Gaide; Montserrat Guzzardi; Emanuela M Iancu; Nathalie Rufer; Nicolas Fasel; Margot Thome
Journal:  Nat Immunol       Date:  2008-02-10       Impact factor: 25.606

3.  T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.

Authors:  Beatrice Coornaert; Mathijs Baens; Karen Heyninck; Tine Bekaert; Mira Haegman; Jens Staal; Lijun Sun; Zhijian J Chen; Peter Marynen; Rudi Beyaert
Journal:  Nat Immunol       Date:  2008-01-27       Impact factor: 25.606

4.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Authors:  Lorena Fontan; Chenghua Yang; Venkataraman Kabaleeswaran; Laurent Volpon; Michael J Osborne; Elena Beltran; Monica Garcia; Leandro Cerchietti; Rita Shaknovich; Shao Ning Yang; Fang Fang; Randy D Gascoyne; Jose Angel Martinez-Climent; J Fraser Glickman; Katherine Borden; Hao Wu; Ari Melnick
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

5.  Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

Authors:  Daniel Nagel; Stefani Spranger; Michelle Vincendeau; Michael Grau; Silke Raffegerst; Bernhard Kloo; Daniela Hlahla; Martin Neuenschwander; Jens Peter von Kries; Kamyar Hadian; Bernd Dörken; Peter Lenz; Georg Lenz; Dolores J Schendel; Daniel Krappmann
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

6.  Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

Authors:  Uta Ferch; Bernhard Kloo; Andreas Gewies; Vera Pfänder; Michael Düwel; Christian Peschel; Daniel Krappmann; Jürgen Ruland
Journal:  J Exp Med       Date:  2009-10-19       Impact factor: 14.307

7.  A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.

Authors:  Michael Düwel; Verena Welteke; Andrea Oeckinghaus; Mathijs Baens; Bernhard Kloo; Uta Ferch; Bryant G Darnay; Jürgen Ruland; Peter Marynen; Daniel Krappmann
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 8.  Multifunctional roles for MALT1 in T-cell activation.

Authors:  Margot Thome
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

9.  Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Stephan Hailfinger; Georg Lenz; Vu Ngo; Anita Posvitz-Fejfar; Fabien Rebeaud; Montserrat Guzzardi; Eva-Maria Murga Penas; Judith Dierlamm; Wing C Chan; Louis M Staudt; Margot Thome
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

10.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Authors:  Alexandar Tzankov; Cecile Meier; Petra Hirschmann; Philip Went; Stefano A Pileri; Stephan Dirnhofer
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941
View more
  2 in total

1.  MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.

Authors:  Jia-Ying Lloyd Lee; Prasanna Ekambaram; Neil M Carleton; Dong Hu; Linda R Klei; Zongyou Cai; Max I Myers; Nathaniel E Hubel; Lidija Covic; Sameer Agnihotri; Daniel Krappmann; Frédéric Bornancin; Adrian V Lee; Steffi Oesterreich; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

2.  Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.

Authors:  Lerisa Govender; Josip Mikulic; Jean-Christophe Wyss; Olivier Gaide; Margot Thome; Dela Golshayan
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.